|Videos|July 5, 2023
Future Perspectives on the Role of Bispecifics in MM
Doctors discuss the potential of bispecific therapies being used in earlier lines of treatment for multiple myeloma, and the need for understanding and reducing toxicities as much as possible.
Advertisement
Episodes in this series
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
2
Screening for CHIP Mutations to Guide CAR T Cell Candidacy in Lymphoma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Daraxonrasib Receives FDA Breakthrough Therapy Status in 1L Metastatic PDAC
5